Don Bailey Net Worth

The estimated Net Worth of Don M Bailey is at least $19 Million dollars as of 8 February 2024. Mr. Bailey owns over 96,155 units of Lineage Cell Therapeutics Inc stock worth over $137,395 and over the last 20 years he sold LCTX stock worth over $18,850,916. In addition, he makes $0 as Independent Director at Lineage Cell Therapeutics Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Mr. Bailey LCTX stock SEC Form 4 insiders trading

Don has made over 9 trades of the Lineage Cell Therapeutics Inc stock since 2008, according to the Form 4 filled with the SEC. Most recently he bought 96,155 units of LCTX stock worth $100,001 on 8 February 2024.

The largest trade he's ever made was selling 221,177 units of Lineage Cell Therapeutics Inc stock on 8 September 2014 worth over $18,850,916. On average, Don trades about 16,409 units every 174 days since 2005. As of 8 February 2024 he still owns at least 158,801 units of Lineage Cell Therapeutics Inc stock.

You can see the complete history of Mr. Bailey stock trades at the bottom of the page.

Don Bailey biography

Don M. Bailey serves as Independent Director of the Company. Mr. Bailey previously served as a director and Chairman of Asterias Biotherapeutics, Inc. (AST) from February 2016 until our acquisition of Asterias in March 2019. Mr. Bailey served as President and Chief Executive Officer of Questcor Pharmaceuticals, Inc. (QCOR), a biopharmaceutical company focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders, from 2007 until Questcor was acquired by Mallinckrodt plc (MNK) in 2014. He was also a director of Mallinckrodt plc from August 2014 to March 2016, and during this time he was the Chairman of its portfolio committee. He initially joined the Questcor board of directors in 2006 as an independent director and chairman of its audit committee. From August 2016 to November 2017, Mr. Bailey served as a director of OncoCyte Corporation (OCX). From June 2015 until its acquisition by Acorda Therapeutics, Inc. (ACOR) in May 2016, Mr. Bailey was also an independent director and chairman of the audit committee of Biotie Therapeutics Corp. (BITI), a clinical-stage pharmaceutical company headquartered in Turku, Finland. Mr. Bailey was an independent director and the non-executive chairman of the board of directors of STAAR Surgical Company (STAA), a leader in the development, manufacture, and marketing of minimally invasive ophthalmic products employing proprietary technologies, from 2005 until 2014. Mr. Bailey served on its audit committee and was chair of its nominating and corporate governance committee. Mr. Bailey was the chairman of the board of directors of Comarco, Inc. (CMRO), a defense services company transformed into a wireless communication products company, from 1998 until 2007, where he served as Chief Executive Officer from 1991 until 2000. Mr. Bailey holds a B.S. degree in mechanical engineering from the Drexel Institute of Technology, an M.S. degree in operations research from the University of Southern California and an M.B.A. from Pepperdine Universit

How old is Don Bailey?

Don Bailey is 74, he's been the Independent Director of Lineage Cell Therapeutics Inc since 2019. There are 1 older and 15 younger executives at Lineage Cell Therapeutics Inc. The oldest executive at Lineage Cell Therapeutics Inc is Alfred Kingsley, 77, who is the Chairman of the Board.

What's Don Bailey's mailing address?

Don's mailing address filed with the SEC is C/O LINEAGE CELL THERAPEUTICS, 2173 SALK AVENUE, SUITE 200, CARLSBAD, CA, 92008.

Insiders trading at Lineage Cell Therapeutics Inc

Over the last 5 years, insiders at Lineage Cell Therapeutics Inc have traded over $2,612,743 worth of Lineage Cell Therapeutics Inc stock and bought 7,879,334 units worth $8,569,904 . The most active insiders traders include Partners, L.P.Broadwood Cap..., Alfred D Kingsley, and Brian M Culley. On average, Lineage Cell Therapeutics Inc executives and independent directors trade stock every 49 days with the average trade being worth of $212,992. The most recent stock trade was executed by Jill Ann Howe on 16 August 2024, trading 10,500 units of LCTX stock currently worth $9,345.

What does Lineage Cell Therapeutics Inc do?

biotime, inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies developed from what we believe to be the world's premier collection of pluripotent cell assets. the foundation of our core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. pluripotent cells have potential application in many areas of medicine with large unmet patient needs, including various age-related degenerative diseases and degenerative conditions for which there presently are no cures. unlike pharmaceuticals that require a molecular target, therapeutic strategies based on the use of pluripotent cells are generally aimed at regenerating or replacing affected cells and tissues, and therefore may have broader applicability than pharmaceutical products.

Complete history of Mr. Bailey stock trades at Staar Surgical Co, Mallinckrodt Plc, Oncocyte, and Lineage Cell Therapeutics Inc

Lineage Cell Therapeutics Inc executives and stock owners

Lineage Cell Therapeutics Inc executives and other stock owners filed with the SEC include:

• Brandi Roberts,
  Chief Financial Officer
• Brian M. Culley M.A., M.B.A.,
  CEO, Pres & Director
• Brian Culley,
  Chief Executive Officer, Director
• Chase Leavitt,
  General Counsel and Corporate Secretary
• Brandi L. Roberts,
  Consultant
• Angus Russell,
  Independent Director
• Michael Mulroy,
  Independent Director
• Stephen Farrell,
  Independent Director
• Neal Bradsher,
  Independent Director
• Don Bailey,
  Independent Director
• Deborah Andrews,
  Independent Director
• Gary Hogge,
  Senior Vice President of Clinical & Medical Affairs
• Alfred Kingsley,
  Chairman of the Board
• Alexandra Hernandez,
  Sr. Director of Fin. & Controller
• Dr. Rami Skaliter,
  Chief Exec. Officer of Cell Cure Neurosciences Ltd.
• William Annett,
  Pres & CEO of OncoCyte Corp.
• Dr. Gary S. Hogge D.V.M., Dvm, Ms, Ph.D.,
  Sr. VP of Clinical & Medical Affairs
• Dr. François Binette M.Sc., Ph.D.,
  Sr. VP & Global Head of R&D
• George A. Samuel III, J.D.,
  Gen. Counsel & Company Sec.
• Ioana C. Hone,
  Director of Investor Relations
• Kevin L. Cook,
  Chief Financial Officer
• George A. Iii Samuel,
  General Counsel/Secretary
• Anula Jayasuriya,
  
• Dipti Amin,
  
• Neal C Bradsher,
  Director
• Alexandra Hernandez,
  Sr Director Finance/Controller
• Kevin Leon Cook,
  Chief Financial Officer
• Jill Ann Howe,
  Chief Financial Officer